Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Neuroblastoma

Unknown

Studies in patient tissue, cell culture and mice suggest 2-O, 3-O-desulfated heparin, a subtype of heparan sulfate, could be useful for treating neuroblastoma. In tissue biopsies from patients with neuroblastoma, high levels of heparan sulfate expression in the stroma correlated with improved prognosis over patients with low stromal heparan sulfate. In cell culture and xenograft models of neuroblastoma, 2-O, 3-O-desulfated heparin decreased tumor growth and increased survival compared with vehicle. Next steps could include identification of molecular targets responsible for the antitumor effect of 2-O, 3-O-desulfated heparin.

SciBX 7(29); doi:10.1038/scibx.2014.861
Published online July 31, 2014

Patent pending; licensing status undisclosed

Knelson, E.H. et al. J. Clin. Invest.; published online June 17, 2014;
doi:10.1172/JCI74270
Contact: Gerard C. Blobe, Duke University Medical Center, Durham, N.C.
e-mail:
gerard.blobe@duke.edu